TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 22689694

Group type: EXPERIMENTAL
Intervention: Respiratory disturbance index (RDI)
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Sleep efficiency
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Serum cortisol (in women)
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Epworth sleepiness score (in women)
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Multiple regression model including RDI, serum cortisol, and urinary norepinephrine
Number of subjects: 126
Study: 19399562

Group type: EXPERIMENTAL
Intervention: External pancreatic duct stent
Number of subjects: 0

Group type: COMPARATOR
Intervention: Octreotide
Number of subjects: 0

Group type: COMPARATOR
Intervention: Internal pancreatic duct stents
Number of subjects: 0

Group type: COMPARATOR
Intervention: Topical or intraductal fibrin glue
Number of subjects: 0
Study: 16728244

Group type: EXPERIMENTAL
Intervention: Calcium hydroxide paste with lentulo‐spiral filler, removed with #15 K‐file agitated irrigation with 17% EDTA (group 2)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Calcium hydroxide paste with lentulo‐spiral filler, removed with ultrasonically agitated irrigation with 17% EDTA (group 3)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Immediate filling with Resilon (group 1)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Positive control with Resilon master point size 40/.04 without sealer
Number of subjects: 47
Study: 15019671

Group type: EXPERIMENTAL
Intervention: Clopidogrel
Number of subjects: 1628

Group type: COMPARATOR
Intervention: Control (non-recipients of clopidogrel)
Number of subjects: 1628
Study: 11560557

Group type: EXPERIMENTAL
Intervention: RTV : SQV 200 : 800 mg (E)
Number of subjects: 8

Group type: COMPARATOR
Intervention: RTV : SQV 400 : 400 mg (B)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Combination regimens (E, F, G)
Number of subjects: 8
Study: 9483394

Group type: EXPERIMENTAL
Intervention: Ultrasound screening during pregnancy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ultrasound exposure
Number of subjects: 0

Group type: COMPARATOR
Intervention: Non-exposure to ultrasound screening
Number of subjects: 0
Study: 8139085

Group type: EXPERIMENTAL
Intervention: Cholestyramine
Number of subjects: 3806

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3806
Study: 2457351

Group type: EXPERIMENTAL
Intervention: Lugol's iodine alone for 10 days pre-operatively (Group I)
Number of subjects: 34

Group type: COMPARATOR
Intervention: ATD and T4 alone until the time of operation (Group II)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: ATD and T4 continued until the day of operation with 10 days' treatment with Lugol's iodine (Group III)
Number of subjects: 34
Study: 30961368

Group type: EXPERIMENTAL
Intervention: Targeted message
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Non-inclusive message
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: No youth message
Number of subjects: 60

Group type: COMPARATOR
Intervention: All messages
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Attention paid to the message
Number of subjects: 60
Study: 31757067

Group type: EXPERIMENTAL
Intervention: Served smaller portion size (Study 2)
Number of subjects: 461

Group type: COMPARATOR
Intervention: Served larger portion size (Study 2)
Number of subjects: 461

Group type: COMPARATOR
Intervention: Visual exposure to portion size (Study 1)
Number of subjects: 461
Study: 28644822

Group type: EXPERIMENTAL
Intervention: Lay-led Chronic Pain Self-Management Programme (CPSMP)
Number of subjects: 424

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 424
Study: 26318271

Group type: EXPERIMENTAL
Intervention: MBCT + mADM (n=33)
Number of subjects: 68

Group type: COMPARATOR
Intervention: mADM alone (n=35)
Number of subjects: 68
Study: 23517506

Group type: EXPERIMENTAL
Intervention: Intensive management (4 weekly review) for 48 weeks
Number of subjects: 206

Group type: COMPARATOR
Intervention: Standard care (12 weekly review) for 48 weeks
Number of subjects: 206

Group type: EXPERIMENTAL
Intervention: Cost-effectiveness analysis at 12, 24, and 28 weeks
Number of subjects: 206
Study: 22051756

Group type: EXPERIMENTAL
Intervention: Dexamethasone (8 mg i.v.) in non-diabetics (n = 20)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Dexamethasone (8 mg i.v.) in type 2 diabetics (n = 15)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Isotonic saline in non-diabetics (control group, n = 20)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Isotonic saline in type 2 diabetics (control group, n = 15)
Number of subjects: 70
Study: 18485394

Group type: EXPERIMENTAL
Intervention: Epirubicin 80 mg/50 ml normal saline plus delayed bacillus Calmette‐Guerin (5 x 10^8 colony‐forming units in 50 ml saline)
Number of subjects: 161

Group type: COMPARATOR
Intervention: Delayed bacillus Calmette‐Guerin alone
Number of subjects: 161

Group type: EXPERIMENTAL
Intervention: Epirubicin plus delayed bacillus Calmette‐Guerin
Number of subjects: 161
Study: 16778364

Group type: EXPERIMENTAL
Intervention: lansoprazole, 30 mg/day
Number of subjects: 30

Group type: COMPARATOR
Intervention: roxatidine, 150 mg/day
Number of subjects: 30
Study: 15589851

Group type: EXPERIMENTAL
Intervention: i.m. P plus phytoestrogens (1,500 mg daily)
Number of subjects: 213

Group type: COMPARATOR
Intervention: i.m. P (50 mg daily) plus placebo
Number of subjects: 213
Study: 11789743

Group type: EXPERIMENTAL
Intervention: Pubovaginal sling
Number of subjects: 46

Group type: COMPARATOR
Intervention: Burch colposuspension
Number of subjects: 46
Study: 8980207

Group type: EXPERIMENTAL
Intervention: Moderate-intensity exercise training (16 weeks, 4 sessions per week, 30-40 minutes each session at 60%-75% of heart rate reserve)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Moderate-intensity exercise training
Number of subjects: 43

Group type: COMPARATOR
Intervention: Wait-listed control condition
Number of subjects: 43
Study: 8512601

Group type: EXPERIMENTAL
Intervention: Dietary, physical activity, and educational interventions
Number of subjects: 423
Study: 3316518

Group type: EXPERIMENTAL
Intervention: Transdermal scopolamine added to metoclopramide and dexamethasone
Number of subjects: 31

Group type: COMPARATOR
Intervention: Metoclopramide and dexamethasone alone
Number of subjects: 31
Study: 31763732

Group type: EXPERIMENTAL
Intervention: Novel combination powder (CP) - HEMOBLAST Bellows; Biom'up, France
Number of subjects: 105

Group type: COMPARATOR
Intervention: Control hemostatic matrix (HM) - FLOSEAL Hemostatic Matrix; Baxter Healthcare Corporation
Number of subjects: 105
Study: 30224318

Group type: EXPERIMENTAL
Intervention: Nintedanib 150 mg twice daily
Number of subjects: 807

Group type: EXPERIMENTAL
Intervention: Nintedanib 100 mg twice daily
Number of subjects: 807

Group type: EXPERIMENTAL
Intervention: Nintedanib
Number of subjects: 807
Study: 28611391

Group type: EXPERIMENTAL
Intervention: High glucosinolate diet for 14 days prior to surgery
Number of subjects: 40

Group type: COMPARATOR
Intervention: Low glucosinolate diet for 14 days prior to surgery
Number of subjects: 40
Study: 26561294

Group type: EXPERIMENTAL
Intervention: Medical therapy at high-enrolling sites
Number of subjects: 0

Group type: COMPARATOR
Intervention: Medical therapy at low-enrolling sites
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combined treatment groups at high-enrolling sites
Number of subjects: 0

Group type: COMPARATOR
Intervention: Combined treatment groups at low-enrolling sites
Number of subjects: 0
Study: 23009249

Group type: EXPERIMENTAL
Intervention: i-SCAN
Number of subjects: 514

Group type: COMPARATOR
Intervention: WL
Number of subjects: 514
Study: 21781409

Group type: EXPERIMENTAL
Intervention: Ecallantide (30 mg subcutaneous)
Number of subjects: 143

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 143
Study: 19309495

Group type: EXPERIMENTAL
Intervention: 0.5% taurolidine/2,500 IU heparin (TRD)
Number of subjects: 120

Group type: COMPARATOR
Intervention: 0.25% povidone-iodine (control)
Number of subjects: 120

Group type: COMPARATOR
Intervention: TRD and Control
Number of subjects: 120
Study: 16394963

Group type: EXPERIMENTAL
Intervention: Weight training plus education (WT + ED)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Weight training (WT)
Number of subjects: 64
Study: 14991469

Group type: EXPERIMENTAL
Intervention: Etodolac 400 mg via gastric tube
Number of subjects: 30

Group type: COMPARATOR
Intervention: Vehicle (control)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Etodolac 400 mg
Number of subjects: 30
Study: 11682375

Group type: EXPERIMENTAL
Intervention: Remifentanil continuous infusion
Number of subjects: 68
Study: 9177060

Group type: EXPERIMENTAL
Intervention: Oral disulfiram
Number of subjects: 24

Group type: COMPARATOR
Intervention: Implanted disulfiram
Number of subjects: 24
Study: 8195550

Group type: EXPERIMENTAL
Intervention: 3-day food record
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: 24-hour recall
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: 5-day food frequency
Number of subjects: 58
Study: 2895829

Group type: EXPERIMENTAL
Intervention: Calcitonin (above 250 micrograms or 50 international units per week)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Oestradiol (positive control)
Number of subjects: 70
Study: 30912285

Group type: EXPERIMENTAL
Intervention: Ketone salts (0.3 g β‐OHB per kg)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Ketone monoester (0.482 g β‐OHB per kg)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study: 29049251

Group type: EXPERIMENTAL
Intervention: Esmolol 0.5 mg/kg
Number of subjects: 16

Group type: COMPARATOR
Intervention: i.v. saline (control group)
Number of subjects: 16
Study: 25670026

Group type: EXPERIMENTAL
Intervention: Biofeedback therapy
Number of subjects: 27

Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 27
Study: 24368165

Group type: EXPERIMENTAL
Intervention: Episodic Future Thinking (EFT) - mentally simulated the sequence of events expected to occur on the second day, including the PM task.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control tasks - participants performed tasks that did not involve mentally simulating future events.
Number of subjects: 0
Study: 23168159

Group type: EXPERIMENTAL
Intervention: Silastic splint placed in the middle meatus for 2 weeks
Number of subjects: 42

Group type: COMPARATOR
Intervention: Nonsplinted sides
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Silastic splint
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Silastic splint and nonsplinted sides
Number of subjects: 42
Study: 20329604

Group type: EXPERIMENTAL
Intervention: Bailing Capsule (BLC)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Control group (mycophenolate mofetil (MMF) plus cyclosporine A (CsA), or tacrolimus (FK506) plus prednisone (Pred))
Number of subjects: 67
Study: 17877513

Group type: EXPERIMENTAL
Intervention: EBAL (esomeprazole 40 mg b.d., bismuth subcitrate 240 mg b.d., amoxicillin 1 g b.d. and levofloxacin 500 mg b.d.)
Number of subjects: 102

Group type: COMPARATOR
Intervention: EBMT (esomeprazole 40 mg b.d., bismuth subcitrate 240 mg b.d., metronidazole 400 mg t.d.s. and tetracycline 500 mg q.d.s.)
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: EBAL
Number of subjects: 102

Group type: COMPARATOR
Intervention: EBMT
Number of subjects: 102
Study: 15617950

Group type: EXPERIMENTAL
Intervention: Maximum likelihood estimate (MLE) based on normality assumptions
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Simulation-extrapolation estimate (SIMEX)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Crude NNT estimation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Empirical data from a randomized study of cholesterol-lowering therapy
Number of subjects: 0
Study: 12693435

Group type: EXPERIMENTAL
Intervention: Education on personal responsibility
Number of subjects: 213

Group type: EXPERIMENTAL
Intervention: Education on dangerousness
Number of subjects: 213

Group type: EXPERIMENTAL
Intervention: Contact with a person with serious mental illness discussing personal responsibility
Number of subjects: 213

Group type: EXPERIMENTAL
Intervention: Contact with a person with serious mental illness discussing dangerousness
Number of subjects: 213

Group type: COMPARATOR
Intervention: No change (control group)
Number of subjects: 213
Study: 9721941

Group type: EXPERIMENTAL
Intervention: mCPP (0.5 mg/kg)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study: 7711623

Group type: EXPERIMENTAL
Intervention: Audit facilitator intervention (n = 1585)
Number of subjects: 3373

Group type: COMPARATOR
Intervention: Control group (n = 1563)
Number of subjects: 3373
Study: 2653325

Group type: EXPERIMENTAL
Intervention: Bezafibrate (400 mg daily for 2 months)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 408607

Group type: EXPERIMENTAL
Intervention: 100 mg iron daily
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: 100 mg iron, 0.44 mg folic acid and 0.66 mg vitamin B12 daily
Number of subjects: 128

Group type: COMPARATOR
Intervention: Placebo (37 pregnant women)
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Combined iron preparation
Number of subjects: 128
Study: 31359804

Group type: EXPERIMENTAL
Intervention: S-amlodipine 5 mg for 10 days followed by S-amlodipine 5 mg plus bisoprolol 5 mg for 7 days
Number of subjects: 32

Group type: COMPARATOR
Intervention: Bisoprolol 5 mg for 7 days followed by S-amlodipine 5 mg plus bisoprolol 5 mg for 10 days
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Both groups monitored for adverse events
Number of subjects: 32
Study: 28926669

Group type: EXPERIMENTAL
Intervention: Health literacy‐considered diabetes self‐management program
Number of subjects: 51
Study: 26632106

Group type: EXPERIMENTAL
Intervention: Pessary use
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: Pessary removal during sex
Number of subjects: 127
Study: 23845398

Group type: EXPERIMENTAL
Intervention: 6-week gym- and home-based exercise program
Number of subjects: 20
Study: 21667769

Group type: EXPERIMENTAL
Intervention: Explicit handwriting program (two weekly sessions of 45 min. over six weeks)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Regular handwriting program (one weekly session)
Number of subjects: 23
Study: 20128337

Group type: EXPERIMENTAL
Intervention: A Matter of Balance program (12-week small-group based balance program)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 23
Study: 16641143

Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation (ergocalciferol 2.5 mg every 3 months, equivalent to a daily dose of 1,100 IU)
Number of subjects: 3717

Group type: COMPARATOR
Intervention: Control group (no vitamin D supplementation)
Number of subjects: 3717
Study: 15575123

Group type: EXPERIMENTAL
Intervention: Preventive home visits by public health nurses over 18 months (mean home visits=4.3)
Number of subjects: 119

Group type: COMPARATOR
Intervention: Usual primary and community care
Number of subjects: 119
Study: 11745967

Group type: EXPERIMENTAL
Intervention: Simplified orthodromic inching test (SOIT)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Orthodromic median‐ulnar latency difference of the 4th digit
Number of subjects: 50
Study: 9416381

Group type: EXPERIMENTAL
Intervention: Bismuth subsalicylate liquid containing Veegum (Pepto‐Bismol)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Bismuth subsalicylate formulation without Veegum
Number of subjects: 11

Group type: COMPARATOR
Intervention: Tetracycline hydrochloride with water (reference treatment)
Number of subjects: 11
Study: 8486198

Group type: EXPERIMENTAL
Intervention: CC/tamoxifen (50 mg CC and 20 mg tamoxifen during cycle days 5 to 9)
Number of subjects: 20

Group type: COMPARATOR
Intervention: CC (100 mg CC during cycle days 5 to 9)
Number of subjects: 20
Study: 3511693

Group type: COMPARATOR
Intervention: Propranolol
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Prazosin
Number of subjects: 10
Study: 29517265

Group type: EXPERIMENTAL
Intervention: Ignoring the prime during the study phase
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Divided attention task on prime presentation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Naming each prime
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Counting the vowels in each prime
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Making a semantic discrimination for each prime
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Memory assessment for not-repeated primes
Number of subjects: 0
Study: 26690310

Group type: EXPERIMENTAL
Intervention: HER2 overexpression
Number of subjects: 3256

Group type: EXPERIMENTAL
Intervention: HER2 amplification by FISH
Number of subjects: 3256

Group type: EXPERIMENTAL
Intervention: HER2-targeted therapy
Number of subjects: 3256
Study: 24486117

Group type: EXPERIMENTAL
Intervention: Mepitel Film
Number of subjects: 78

Group type: COMPARATOR
Intervention: Aqueous cream
Number of subjects: 78
Study: 22065400

Group type: COMPARATOR
Intervention: bosutinib 500 mg with food (therapeutic)
Number of subjects: 60

Group type: COMPARATOR
Intervention: bosutinib 500 mg plus ketoconazole (supratherapeutic)
Number of subjects: 60

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 60

Group type: COMPARATOR
Intervention: moxifloxacin
Number of subjects: 60
Study: 16020405

Group type: EXPERIMENTAL
Intervention: Valsartan 80 mg/day (increased to 160 mg as tolerated)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Enalapril 5 mg/day (increased to 10 mg as tolerated)
Number of subjects: 42
Study: 11835026

Group type: EXPERIMENTAL
Intervention: CEC adjudicated MIs
Number of subjects: 5225

Group type: COMPARATOR
Intervention: Investigator assessments
Number of subjects: 5225

Group type: EXPERIMENTAL
Intervention: Agreement with CEC assessments
Number of subjects: 5225

Group type: COMPARATOR
Intervention: Disagreements confirmed
Number of subjects: 5225
Study: 9857885

Group type: EXPERIMENTAL
Intervention: Lamifiban (GP IIb/IIIa inhibitor)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 7832332

Group type: EXPERIMENTAL
Intervention: Sevoflurane with nitrous oxide (group SN)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Halothane with nitrous oxide (group HN)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Sevoflurane (group S)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Halothane (group HN)
Number of subjects: 120
Study: 2212410

Group type: EXPERIMENTAL
Intervention: Shrimp-specific IgG2
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Shrimp-specific IgG4
Number of subjects: 51

Group type: COMPARATOR
Intervention: DBPCFC (double-blind, placebo-controlled food challenge)
Number of subjects: 51
Study: 574523

Group type: EXPERIMENTAL
Intervention: Inhalation of fenoterol (beta 2‐receptor stimulator)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Inhalation of Freons
Number of subjects: 18
Study: 31371434

Group type: EXPERIMENTAL
Intervention: Deferred cord clamping (≥2 min)
Number of subjects: 276

Group type: COMPARATOR
Intervention: Immediate clamping (≤20 s)
Number of subjects: 276
Study: 30245732

Group type: EXPERIMENTAL
Intervention: Mantra Meditation (MM)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Music Listening (ML)
Number of subjects: 22
Study: 27763958

Group type: EXPERIMENTAL
Intervention: InterTAN intramedullary device (n = 123)
Number of subjects: 249

Group type: COMPARATOR
Intervention: Sliding hip screw (n = 126)
Number of subjects: 249
Study: 26264767

Group type: EXPERIMENTAL
Intervention: Concomitant high tibial osteotomy (HTO) and anterior cruciate ligament (ACL) reconstruction
Number of subjects: 33
Study: 23756346

Group type: EXPERIMENTAL
Intervention: Fish oil capsules (750mg docosahexaenoic plus eicosapentaenoic acids, and 60mg gamma linolenic acid/school day) during Phase 1
Number of subjects: 409

Group type: COMPARATOR
Intervention: Placebo during Phase 1
Number of subjects: 409

Group type: EXPERIMENTAL
Intervention: Fish oil capsules (after crossover in Phase 2)
Number of subjects: 409
Study: 20087760

Group type: EXPERIMENTAL
Intervention: 8 pulses ATP
Number of subjects: 925

Group type: EXPERIMENTAL
Intervention: 15 pulses ATP
Number of subjects: 925
Study: 18856250

Group type: EXPERIMENTAL
Intervention: Timed oral care (toothbrushing every 8 hours)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Usual oral care (control group)
Number of subjects: 24
Study: 16243588

Group type: EXPERIMENTAL
Intervention: Elemene injections
Number of subjects: 127
Study: 14600700

Group type: EXPERIMENTAL
Intervention: Ultrasound/doppler examination
Number of subjects: 20

Group type: COMPARATOR
Intervention: Periapical radiographs
Number of subjects: 20
Study: 11111130

Group type: EXPERIMENTAL
Intervention: 0.9 g of n-3 PUFA/day as fish oil capsule
Number of subjects: 25

Group type: COMPARATOR
Intervention: 0.9 g of n-3 PUFA/day from enriched foods
Number of subjects: 25
Study: 8686411

Group type: EXPERIMENTAL
Intervention: High potency pancreatin (9 g, 3 g x 3 times) for approximately 1 month
Number of subjects: 12
Study: 1422647

Group type: EXPERIMENTAL
Intervention: Malleotrain
Number of subjects: 220
Study: 3900905

Group type: EXPERIMENTAL
Intervention: Rifampin, 20 mg/kg, once daily for four days
Number of subjects: 492

Group type: EXPERIMENTAL
Intervention: Rifampin, 10 mg/kg, twice a day for four days
Number of subjects: 492

Group type: COMPARATOR
Intervention: Placebo, once daily for four days
Number of subjects: 492

Group type: EXPERIMENTAL
Intervention: All drug regimens (including placebo)
Number of subjects: 492

Group type: EXPERIMENTAL
Intervention: Anticapsular antibody concentration measurement
Number of subjects: 492
Study: 30935617

Group type: COMPARATOR
Intervention: K3XF rotary system with continuous rotary movement
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: K3XF rotary system with adaptive movement
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Twisted File adaptive file with adaptive movement
Number of subjects: 45
Study: 29750971

Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin (8 IU)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin (24 IU)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Intravenous oxytocin (1 IU)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 26808973

Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Cognitive Therapy (MBCT)
Number of subjects: 173

Group type: COMPARATOR
Intervention: Health Enhancement Program (HEP)
Number of subjects: 173
Study: 24839144

Group type: EXPERIMENTAL
Intervention: Lactoferrin (LF) 200 mg/d
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50

Group type: COMPARATOR
Intervention: Healthy term neonates
Number of subjects: 50
Study: 21875758

Group type: EXPERIMENTAL
Intervention: Latanoprost 0.1%
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16